Sovihep and Dacihep online from India Supplier & Exporter
Sofosbuvir is an NS5B RNA polymerase inhibitor that suppresses hepatitis C virus replication (multiplication). This is the latest preparation of direct antiviral action.
The drug acts directly on the hepatitis C virus. Sofosbuvir blocks the main stages of virus multiplication. It is used to treat patients with the first, second, third and fourth genotype of the virus. For treatment of the first and fourth genotype, a combination of Sofosbuvir with pegylated interferon and ribavirin is required, for the second and third only Ribavirin. The treatment regimen is altered depending on the presence of liver cirrhosis and how the patient responded to previous therapy.
Daclatasvir is a powerful new generation drug, a pan-genotype inhibitor of the NS5A replication complex. It is used to treat all genotypes of the hepatitis C virus.
The active substance of the drug – Daclatasvir – blocks the virus in the cells of the body without allowing it to get into the blood and multiply it. To maximize the efficacy of the drug, it is used together with other antiviral drugs. How to take daclatasvir instructions and admission regimes for each genotype are described in this article.
Daclatasvir is officially approved for use in combination with other antiviral agents (sofosbuvir) for the treatment of the first, second, third and fourth hepatitis C virus genotypes in adult patients. Daclatasvir and Sofosbuvir are the first oral regimen for the treatment of hepatitis C without the use of highly effective interferon. Practically, the 100 percent marker during clinical trials was reached even in patients with hepatic pathology and in patients with a third genotype of the virus.
Clinical trials have confirmed the efficacy of a combination of sofosbuvir and daclatasvir in the treatment of HCV genotypes from one to four, including coinfection with hepatitis and patients waiting for a liver transplant.
Drugs are given orally on a single tablet of each type once a day. The duration of therapy is 12 weeks for simple cases, 24 weeks for more complicated cases and is determined by the attending physician. Sometimes, the action of SoviHep and DaciHep is enhanced by ribavirin, which has not yet been eliminated.
Sofosbuvir and daclatasvir should not be used in the following cases:
• hypersensitivity to one of the substances;
• women’s therapy during pregnancy and lactation;
• The need to treat children and adolescents under the age of 18 years.
To exclude pregnancy, women of childbearing potential are required to use the most effective contraceptive methods when administering Sovihep and Dacihep, one of the partners. The same measures are taken within 6 months of treatment.
Sofosbuvir and daclatasvir online in India
Buying sofosbuvir and daclatasvir from India is a great option; just make sure the provider should be licensed. You can “buy sofosbuvir & daclatasvir online” at a reduced price by contacting us.